Total Payments
$778,507
2024 Payments
$250,486
Companies
29
Transactions
408
Medicare Patients
839
Medicare Billing
$119,876
Payment Breakdown by Category
Consulting$550,437 (70.7%)
Travel$117,684 (15.1%)
Other$99,306 (12.8%)
Food & Beverage$8,014 (1.0%)
Research$3,065 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $550,437 | 140 | 70.7% |
| Travel and Lodging | $117,684 | 104 | 15.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $89,131 | 30 | 11.4% |
| Honoraria | $8,925 | 2 | 1.1% |
| Food and Beverage | $8,014 | 129 | 1.0% |
| Unspecified | $3,065 | 2 | 0.4% |
| Charitable Contribution | $1,250 | 1 | 0.2% |
Payments by Type
General
$775,442
406 transactions
Research
$3,065
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $92,752 | 74 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $86,379 | 65 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $65,385 | 44 | $0 (2024) |
| Amgen Inc. | $63,433 | 29 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $60,217 | 23 | $0 (2024) |
| ROCHE DIAGNOSTICS INTERNATIONAL LTD | $55,724 | 20 | $0 (2024) |
| Novo Nordisk AS | $46,799 | 11 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $42,731 | 10 | $0 (2024) |
| Eli Lilly and Company | $35,248 | 15 | $0 (2024) |
| Novo Nordisk Inc | $34,834 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $250,486 | 104 | Lexicon Pharmaceuticals, Inc. ($42,731) |
| 2023 | $119,881 | 78 | Novo Nordisk AS ($22,543) |
| 2022 | $183,437 | 102 | Bayer HealthCare Pharmaceuticals Inc. ($34,996) |
| 2021 | $46,252 | 28 | Bayer HealthCare Pharmaceuticals Inc. ($13,999) |
| 2020 | $65,449 | 28 | Amgen Inc. ($27,558) |
| 2019 | $73,998 | 57 | Amgen Inc. ($35,680) |
| 2018 | $37,666 | 9 | Bayer HealthCare Pharmaceuticals Inc. ($20,680) |
| 2017 | $1,337 | 2 | Medtronic Vascular, Inc. ($1,250) |
All Payment Transactions
408 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $6,571.86 | General |
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| 12/18/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $453.78 | General |
| 12/18/2024 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $32.72 | General |
| 12/18/2024 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $12.76 | General |
| 12/18/2024 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $12.76 | General |
| 12/13/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $195.47 | General |
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,520.00 | General |
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,720.00 | General |
| 12/11/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Consulting Fee | Cash or cash equivalent | $2,285.00 | General |
| 12/11/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,828.00 | General |
| 12/11/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Travel and Lodging | In-kind items and services | $362.77 | General |
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,074.00 | General |
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Consulting Fee | Cash or cash equivalent | $2,685.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/25/2024 | Eli Lilly and Company | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Diabetes | ||||||
| 11/17/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| 11/16/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $32.72 | General |
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Travel and Lodging | In-kind items and services | $362.77 | General |
| 11/15/2024 | ROCHE DIAGNOSTICS INTERNATIONAL LTD | — | Food and Beverage | In-kind items and services | $159.84 | General |
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $74.28 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $70.00 | General |
| Category: Cardio-renal | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $1,815 | 1 |
| A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL) | SANOFI-AVENTIS U.S. LLC | $1,250 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 233 | 424 | $156,577 | $32,355 |
| 2022 | 9 | 220 | 359 | $132,680 | $26,824 |
| 2021 | 8 | 223 | 400 | $153,478 | $33,534 |
| 2020 | 6 | 163 | 318 | $127,586 | $27,164 |
Total Patients
839
Total Services
1,501
Medicare Billing
$119,876
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 53 | 218 | $65,300 | $14,604 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 73 | 97 | $39,226 | $7,434 | 19.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 37 | 37 | $20,265 | $4,073 | 20.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 39 | 39 | $11,865 | $2,693 | 22.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 20 | 22 | $13,178 | $2,494 | 18.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 11 | 11 | $6,743 | $1,056 | 15.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 59 | 177 | $50,357 | $10,204 | 20.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 42 | 56 | $22,288 | $4,332 | 19.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 25 | 25 | $13,473 | $2,873 | 21.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 15 | $11,851 | $2,540 | 21.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 19 | 19 | $10,639 | $2,005 | 18.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 19 | 19 | $8,037 | $1,716 | 21.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 20 | $8,149 | $1,657 | 20.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 14 | 14 | $4,122 | $863.24 | 20.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 14 | $3,764 | $633.64 | 16.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 46 | 171 | $49,209 | $10,634 | 21.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 29 | 68 | $28,234 | $6,079 | 21.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 53 | $18,546 | $4,460 | 24.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 23 | 23 | $18,579 | $3,864 | 20.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 35 | 35 | $15,111 | $3,253 | 21.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 20 | 20 | $10,586 | $2,258 | 21.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 15 | $8,233 | $1,764 | 21.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 13 | 15 | $4,980 | $1,222 | 24.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 37 | 115 | $48,355 | $10,456 | 21.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 25 | 95 | $27,757 | $5,955 | 21.5% |
About Muthiah Vaduganathan, MD, MPH
Muthiah Vaduganathan, MD, MPH is a Cardiovascular Disease healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2012. The National Provider Identifier (NPI) number assigned to this provider is 1023370467.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Muthiah Vaduganathan, MD, MPH has received a total of $778,507 in payments from pharmaceutical and medical device companies, with $250,486 received in 2024. These payments were reported across 408 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($550,437).
As a Medicare-enrolled provider, Vaduganathan has provided services to 839 Medicare beneficiaries, totaling 1,501 services with total Medicare billing of $119,876. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Internal Medicine
- Location Boston, MA
- Active Since 06/12/2012
- Last Updated 07/23/2019
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1023370467
Products in Payments
- Kerendia (Drug) $61,656
- JARDIANCE (Drug) $50,838
- Non-Covered $30,885
- FARXIGA (Drug) $27,425
- MULTAQ (Drug) $23,205
- MONOFERRIC (Drug) $23,009
- Fluid Systems - Non Prod Related (Biological) $21,028
- INJECTAFER (Drug) $20,744
- KENGREAL (Drug) $8,797
- BREZTRI (Drug) $5,929
- LEQVIO (Drug) $5,704
- Elecsys Troponin T Gen 5 STAT (Device) $4,870
- Ozempic (Drug) $4,500
- Veltassa (Drug) $3,721
- Tryvio (Drug) $3,540
- Repatha (Biological) $2,750
- LOKELMA (Drug) $2,698
- ENTRESTO (Drug) $2,447
- Monoferric (Drug) $2,400
- VERQUVO (Drug) $1,278
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Boston
Dr. Elizabeth Nabel, M.d, M.D
Cardiovascular Disease — Payments: $3.0M
Cardiovascular Disease $3.0M
Kenneth Rosenfield, M.d, M.D
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Eric Secemsky, Md, Msc, MD, MSC
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
Dr. Benjamin Scirica, M.d, M.D
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Jorge Plutzky, Md, MD
Cardiovascular Disease — Payments: $973,823
Cardiovascular Disease $973,823
Christopher Cannon, Md, MD
Cardiovascular Disease — Payments: $869,405
Cardiovascular Disease $869,405